Novo Nordisk will bring 52 abstracts to the European Congress on Obesity (ECO) in Istanbul, May 12–15, spotlighting its obesity franchise across three fronts: higher-dose Wegovy (semaglutide 7.2 mg), the once-daily Wegovy pill (oral semaglutide 25 mg), and the investigational amylin/GLP-1 combo CagriSema. The program spans randomized trials and real-world evidence, including responder analyses for dose intensification, cardiovascular and women’s health subgroups, and indirect comparisons of oral semaglutide versus an emerging oral GLP-1 competitor.
Beyond scientific breadth, the agenda reads like a commercialization blueprint for the next phase of the obesity market. Novo Nordisk is positioning a three-tiered strategy: accelerate uptake of the oral pill as a convenience-led front door to therapy, validate the 7.2 mg injectable dose to overcome weight-loss plateaus and fortify outcomes, and prime the market for next-generation combination biology with CagriSema. The strategic question is whether this evidence package can persuade payers to widen access while defending share against intensifying competition from rival oral GLP-1s and multi-agonists.
Timing matters. With the Wegovy pill already FDA-approved and still pending in Europe, evidence on early responders from OASIS 4 and data in people with impaired physical function could help primary care adoption and payer triage, particularly in systems seeking rapid, measurable weight-loss thresholds. An indirect comparison versus orforglipron underscores the head-to-head narrative taking shape ahead of broader oral GLP-1 launches. For injectables, STEP UP analyses of semaglutide 7.2 mg focusing on time to clinically meaningful weight-loss milestones, durability, and eating control are designed to operationalize dose escalation pathways. If these data convincingly link higher dosing to faster goal attainment without disproportionate tolerability trade-offs, formularies may codify responder-based step-ups instead of switching to competitors.
The whole-patient framing is equally pointed. Subgroup findings from SELECT in peri- and postmenopausal women and real-world analyses exploring menopausal symptoms and antimigraine medication use signal an effort to embed obesity treatment within women’s health and neurovascular care. For payers, outcomes that touch cardiovascular risk and functional status strengthen arguments for broader eligibility and outcomes-based contracts. For HCPs, practical guidance on identifying early responders and aligning dose or modality to patient preferences (injectable versus pill) can streamline initiation and reduce abandonment.
CagriSema is the forward scout for the post-GLP-1 era. REDEFINE 1 readouts on body composition, muscle strength, waist-to-height ratio, predicted atherosclerotic cardiovascular disease risk, and dose–response offer answers to two pressure points in obesity care: preserving lean mass while maximizing fat loss and translating weight reduction into cardiometabolic risk modification. If the combination consistently outperforms GLP-1 monotherapy on composition and functional endpoints, it could narrow the perceived advantage of dual incretin competitors and set the bar for the next standard of care.
For Commercial and Medical Affairs leaders, the immediate work is clear: convert responder analytics into payer algorithms and titration protocols, equip primary care with modality selection playbooks, and expand real-world evidence to sustain coverage on cardiovascular and functional outcomes. The broader industry trend—biotech and Big Pharma converging on combination biology and convenient oral delivery—will sharpen competitive price-value debates. What to watch at ECO: the credibility of the oral semaglutide indirect comparison, the tolerability-performance balance at 7.2 mg, and whether CagriSema’s body-composition and risk signals are strong enough to reset expectations for combination therapy. The next question is not if demand will persist, but which evidence will determine who gets paid, how fast patients progress, and what “good” looks like in obesity care in 2027 and beyond.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
